TELA Bio Announces Changes to its Board of Directors
June 02 2021 - 7:00AM
TELA Bio, Inc. ("TELA"), a commercial-stage medical technology
company focused on designing, developing, and marketing innovative
tissue reinforcement materials to address unmet needs in soft
tissue reconstruction, today announced that it has appointed John
Nosenzo, the Chief Commercial Officer of Bioventus Inc., to its
board of directors effective June 2, 2021.
Concurrent with the appointment of John Nosenzo, as previously
announced, our current board member Adele Olivia will be stepping
down. Following these changes, TELA Bio's board will be composed of
seven directors, six of whom are independent.
"I am very excited to welcome John to TELA Bio. His vast
knowledge and experience in healthcare will be a valued addition to
TELA Bio," said Antony Koblish, President and CEO of TELA Bio.
"John has proven to be a strong leader throughout his career and
has gained extensive experience in healthcare marketing and sales.
We are looking forward to working with John and are privileged to
have such a talented professional join us."
Koblish added, "Additionally, I would like to thank Adele for
her time on the board and her long-standing commitment to TELA Bio.
She has been a wonderful addition and added an impactful value. Her
experience and knowledge of the medtech industry will be sorely
missed, and we wish her the best."
About John Nosenzo
Mr. Nosenzo has served as the Chief Commercial Officer of
Bioventus Inc., a global leader in innovations for active healing,
since February 2017. Before joining Bioventus, Mr. Nosenzo spent
six years at Beckman Coulter serving as its Senior Vice President,
Global Customer Operations. Previously, Mr. Nosenzo spent six years
with Siemens serving as Vice President of Sales, Medical Testing
Systems before being promoted to Senior Vice President, General
Manager - Americas, and later as Senior Vice President, Customer
Relations Management. Mr. Nosenzo also spent time at Quest
Diagnostics serving as Vice President, Marketing and Sales. Mr.
Nosenzo began his long career in healthcare with Bayer Healthcare,
dedicating 15 years to their pharmaceutical division in various
sales roles, including Vice President of Sales, Generic Product
Division and later, Vice President of Marketing and Sales,
Specialty Products of the Schein Pharmaceutical Division. Mr.
Nosenzo received an MBA from Adelphi University in marketing and
management and holds a Bachelor of Science from St. John's
University in pharmacy.
About TELA Bio, Inc.
TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical
technology company focused on designing, developing, and marketing
innovative tissue reinforcement materials to address unmet needs in
soft tissue reconstruction. The company is committed to providing
patients with advanced, economically effective biologic material
repair solutions to minimize long-term exposure to permanent
synthetic materials and improve clinical outcomes. TELA Bio's
OviTex® and OviTex PRS Reinforced Tissue Matrix products are
purposefully designed to address the shortcomings of existing
reinforcement materials in hernia repair, abdominal wall
reconstruction, and plastic and reconstructive surgery. For more
information, visit www.telabio.com.
Caution Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "predict,"
"forecast," "project," "plan," "intend" or similar expressions, or
statements regarding intent, belief, or current expectations are
forward-looking statements and reflect the current beliefs of
TELA's management. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
other factors that could cause actual results and events to differ
materially and adversely from those indicated by such
forward-looking statements including, among others, the impact to
our business of the ongoing COVID-19 pandemic, including any impact
on our ability to market our products, demand for our products due
to deferral of procedures using our products or disruption in our
supply chain, our ability to achieve or sustain profitability, our
ability to gain market acceptance for our products and to
accurately forecast and meet customer demand, our ability to
compete successfully, that data from earlier studies related to our
products and interim data from ongoing studies may not be
replicated in later studies or indicative of future data, our
ability to enhance our product offerings, development and
manufacturing problems, capacity constraints or delays in
production of our products, maintenance of coverage and adequate
reimbursement for procedures using our products, product defects or
failures. These and other risks and uncertainties are described
more fully in the "Risk Factors" section and elsewhere in our
filings with the Securities and Exchange Commission and available
at www.sec.gov, including in our Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. Any forward-looking statements
that we make in this announcement speak only as of the date of this
press release, and TELA assumes no obligation to update
forward-looking statements whether as a result of new information,
future events or otherwise after the date of this press release,
except as required under applicable law.
TELA Bio ContactNora BrennanChief Financial
OfficerTELA Bio, Inc.484-320-2930Investor
ContactGreg Chodaczek347-620-7010 ir@telabio.com
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Mar 2024 to Apr 2024
TELA Bio (NASDAQ:TELA)
Historical Stock Chart
From Apr 2023 to Apr 2024